Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
PHYsics for a greener world: fostering the NExt generation of talented young researchers in novel materials, innovative STrategies and energy solutions (PHYNEST)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Co-funding of regional, national and international programmes
Action type: Marie Skłodowska-Curie actions
Countries involved: Spain,Chile,United States,Denmark,Italy,Germany,Sweden,United Kingdom,Austria,Finland,France,Canada,Czechia
Call: MSCA COFUND 2024 (HORIZON-MSCA-2024-COFUND-01, 2024)
Start date: 2026-01-01
End date: 2030-12-31
Duration (months): 60.0
Total project cost (EUR): 3960000.0
EU funding (EUR): 3960000.0
Participants: 25
Project status: SIGNED

PHYNEST (“PHYsics for a greener world: fostering the NExt generation of talented young researchers in novel materials, innovative STrategies and energy solutions") is a unique doctoral programme for talented 25 PhD candidates, led by Universitat Autònoma de Barcelona (UAB). PHYNEST aims to train tomorrow’s leaders in the field of advanced materials, innovative strategies, and key solutions to help migrate towards a new energy paradigm and to enhance environmental sustainability, taking physical sciences as the backbone. Together with UAB, 5 internationally-renowned research centres as Implementing Partners will embark on this exciting adventure after selecting and recruiting doctoral candidates from all over the world in an open, transparent and merit-based process. Special attention will be paid to applications from women, which have been chronically underrepresented in STEM disciplines, and other minority groups. Cutting edge research topics will be offered to the PhD candidates (+50 options) in which experimental and theoretical research, as well as the historical and social dimension of energy and climate, will be tackled in a highly collaborative, multidisciplinary and innovative manner. The hosting institutions count with world-class research infrastructures and a pool of accomplished supervisors in their respective fields. +20 Associated Partners will participate in PHYNEST to host the fellows for secondments and/or participate in the network-wide events of the network to offer high-quality scientific and transferable skills training in different domains, ranging from diversity equity and inclusion, time and project management, to effective communication to diverse audiences. PHYNEST is the perfect nest for nurturing young researchers, preparing them to become the next generation of academic and entrepreneurial leaders committed to a greener future.

Keywords: energy materials devices climate change sustainability modelling
Trustworthy AI for CCAM (AI4CCAM)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Climate, Energy and Mobility
Theme: Mobility
Destination: Safe, Resilient Transport and Smart Mobility services for passengers and goods
Action type: Research and Innovation actions
Partnership: CCAM (co-programmed)
Countries involved: Norway,Greece,Spain,France,Italy,Belgium,Germany,Czechia,Austria
Call: Artificial Intelligence (AI): Explainable and trustworthy concepts, techniques and models for CCAM (CCAM Partnership) (HORIZON-CL5-2022-D6-01, 2022)
Start date: 2023-01-01
End date: 2026-03-31
Duration (months): 39.0
Total project cost (EUR): 5965630.0
EU funding (EUR): 5965630.0
Participants: 15
Project status: SIGNED

Considering Artificial Intelligence (AI) capabilities and potential risks, and taking into account its limitations, AI4CCAM will develop an open environment for integrating trustworthy-by-design AI models of vulnerable road user behaviour anticipation in urban traffic conditions, and accounting for improved road safety and user acceptance. Leveraging the Trustworthy AI guidelines for general intelligent software systems and the ethics recommendations for connected automated vehicles, AI4CCAM will support AI-based scenarios management in which pedestrian/cyclist behaviour anticipation models will integrate visual gaze estimation and where explainable ego car trajectory prediction models are simulated with ethical dilemmas and multiplied with generative adversarial networks and metamorphic testing techniques. The AI4CCAM open environment will include an interoperable digital framework for managing and generating AI-based urban-traffic scenarios in which trustworthy-by-design AI models can be tested and an online participatory space to foster acceptance of AI in automated driving, determine AI risks and identify biases in datasets and cyber-threats. Simulation scenarios of road users interacting with automated vehicles will be developed and evaluated in three complementary use cases covering the whole sense-plan-act paradigm and user acceptance. As such, the project will advance knowledge in building trustworthy-by-design AI-based solutions for CCAM applications.

Keywords: trustworthy by design ai vrus movement anticipation models generative adversarial networks metamorphic testing
Commercial Fusion Energy with Short-Pulse High-Intensity Lasers and Nanostructured Fuel Targets (CFE-NANO)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Germany
Call: EIC Accelerator Open 2024 (HORIZON-EIC-2024-ACCELERATOR-02, 2024)
Start date: 2024-10-01
End date: 2027-03-31
Duration (months): 30.0
Total project cost (EUR): 3556030.7
EU funding (EUR): 2489221.49
Participants: 1
Project status: SIGNED

To achieve climate targets while maintaining industrial value creation and prosperity in Europe, EU companies must be able to switch to clean and competitive energy. Marvel Fusion (“MF”), founded in Munich in 2019, pursues a new and fast-track to commercialize fusion energy. The unique approach builds on the laser-fusion concept of the National Ignition Facility (“NIF”), where energy gain was demonstrated for the first time in 2022. With diode-pumped laser systems, nanostructured targets and the use of mixed fuels, MF bypasses the main problems of traditional fusion concepts to achieve a commercially viable power plant concept. MF has performed more than 2,000 experiments over the past three years to validate its approach. With the completion of the demonstration facility in Colorado by 2027 with two proprietary laser systems developed in collaboration with SPRIN-D, MF will reach a full proof-of-technology – with infrastructure and laser of the facility already fully funded. Afterwards, MF will build a pilot powerplant by 2033 with 100 MW output, with Siemens Energy as development partner. To achieve their ambitious goals, MF has assembled a world-class team of scientists and entrepreneurs, and a network of academic and industrial partners, including collaborations with Colorado State (“CSU”), Stanford, and LMU. Furthermore, European companies like Thales and Siemens Energy assist MF in the development and industrialization of MF’s technology.

Keywords: fusion energy,laser,nuclear fusion,nanofabrication,inertial fusion energy,power plant,future energy market,clean energy
Identification of long-term therapeutic strategy in IgE-mediated allergy by leveraging humanized models and patient samples (HumanIgE)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Immunity, Infection and I mmunotherapy
Panel description: The immune system , related disorders  and their mechanisms , biology of infectious agents and infection, biological basis of prevention and treatment of infectious diseases , innovative imm unological tools and approaches , including  therapies
Countries involved: France
Call: ERC CONSOLIDATOR GRANTS (ERC-2021-COG, 2021)
Start date: 2023-03-01
End date: 2028-02-29
Duration (months): 60.0
Total project cost (EUR): 1999431.0
EU funding (EUR): 1999431.0
Participants: 1
Project status: SIGNED

IgE is a key driver of allergic diseases, which affect approximately one-third of the world’s population. Monoclonal antibodies (mAbs) targeting IgE are approved for the treatment of allergic asthma, and show clinical benefit in a number of other allergic diseases. Yet, a sizable portion of patients do not respond to the drug despite high levels of IgE. There is a clear need to better define which allergy features depend (or not) on IgE, and to find predictive biomarkers in order to identify patients who will benefit from anti-IgE therapy. In addition, use of anti-IgE mAbs is limited by very high cost and the need to perform frequent reinfusion to maintain clinical efficiency. Combining unique mouse models humanized for IgE and its two receptors FceRI and CD23, clinical samples from patients undergoing FDA-approved anti-IgE therapy, and a novel high-throughput IgE repertoire analysis method, the project addresses three key questions: (1) Which IgE features distinguish responders vs. non-responders to anti-IgE therapy, and can it be used as predictive biomarker? (2) Which key allergy features depend on IgE, and through which mechanisms? (3) Can we induce long-term protection against IgE-mediated allergies with a vaccine approach? This translational project will increase our understanding of the basic mechanisms underlying allergic diseases, and has the potential to identify important new therapeutic strategies.

Keywords: ige,allergy,asthma,mast cell,antibody
ALK-driven cancers: a Portfolio of ONcoimmunoTherapies to achieve tumor Eradication (A-PONTE)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Physiology in Health, Disease and Ageing
Panel description: Organ and tissue physiology, comparative physiology, physiology  of ageing , pathophysiology, inter - organ and tissue communication, endocrinology, nutrition,  metabolism, interaction with the microbiome, non -communicable diseases including cancer (and except disorders of the nervous system  and immunity -related diseases)
Countries involved: Italy
Call: ERC ADVANCED GRANTS (ERC-2024-ADG, 2024)
Start date: 2026-01-01
End date: 2030-12-31
Duration (months): 60.0
Total project cost (EUR): 2497392.0
EU funding (EUR): 2497392.0
Participants: 1
Project status: SIGNED

Cancers driven by the oncogenic activation of the ALK gene include subsets of non-small cell lung cancer, lymphoma, neuroblastoma, melanoma, glioblastoma, thyroid cancer, stromal tumors and other hematologic malignancies and solid tumors. Typically, these cancers affect children or young adults in healthy conditions with a long expectancy of life. They are currently treated with ALK tyrosine kinase inhibitors (TKIs) either in first line or at relapse after other standard therapies. ALK TKIs reduce tumor burden dramatically, and often induce a prolonged state of minimal residual disease (MRD) resulting in several years of extended survival. Eventually, most ALK+ tumors become resistant to ALK TKIs by different mechanisms. Relapses occur in >90% of patients that are then left without efficacious therapies and face a dismal prognosis. This common pattern of evolution of ALK+ tumors, characterized by a prolonged state MRD before the fatal relapse, provides a window of opportunity to develop therapies that might be curative should ALK+ persister cells be fully eradicated. In this proposal, we will develop, test and validate a portfolio of ALK-directed T cell immunotherapies to achieve eradication of residual ALK+ cells during the MRD state induced by ALK TKIs. These immunotherapies include potentiated ALK.CAR-T cells for tumors that express ALK on the surface, and ALK.TCR-T cells for tumors that express ALK internally in the cytoplasm. ALK-directed T cell immunotherapies will be tested alone or in novel modalities of combination between them, with ALK vaccines or with other approaches to further potentiate their anti-tumoral efficacy. We will empower these ALK immunotherapies to eradicate MRD based on the ALK genetic alteration that is specific to each tumor. We envision that the combination of ALK TKIs with ALK-directed T cell immunotherapies could achieve a complete cure in a large subset of patients with ALK+ tumors before the onset of relapse or metastatic spread.

Keywords: alk cancer,car t,tcr t,cellular immunotherapies for cancer,cancer vaccines,lung cancer,lymphoma,neuroblastoma
Conformal Blocks through Integrability and Probability (ConBIP)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Mathematics
Countries involved: United Kingdom
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2025-08-01
End date: 2027-07-31
Duration (months): 24.0
Total project cost (EUR): 276187.92
EU funding (EUR): 276187.92
Participants: 1
Project status: SIGNED

In the past decade, two major breakthroughs have significantly advanced mathematical physics. The first established a crucial link between the correlation functions of two-dimensional conformal field theories (2D CFTs)—known as conformal blocks—and a special class of integrable systems called the Painlevé equations. This connection, known as the Painlevé/CFT correspondence, led to the derivation of closed-form expressions for the highly transcendental solutions of the Painlevé equations, solving a long-standing problem. The second breakthrough provided a rigorous formulation of certain 2D CFTs through probabilistic frameworks such as Gaussian Multiplicative Chaos (GMC) measures and Conformal Loop Ensembles (CLE). These concepts have granted unprecedented analytic control over CFTs, particularly in the context of conformal blocks. This project aims to bridge these two approaches using Random Matrix Theory to develop a unified framework. Achieving this goal is both ambitious and highly desirable, as it would uncover a universal structure underlying CFTs and resolve critical conjectures in both mathematics and physics.

Keywords: conformal blocks,gmc measures,heun equations,painlev equations,random matrices
Towards a Mechanistic Understanding of Nanoparticle Interactions with Exosome Secretion (NanoEXOS)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Ireland
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2023-09-01
End date: 2025-08-31
Duration (months): 24.0
Total project cost (EUR): 199694.4
EU funding (EUR): 199694.4
Participants: 1
Project status: SIGNED

In recent decades, considerable progress has been made in bio-nano research towards a growing understanding of the interaction mechanisms between nanoparticles (NPs) and living systems. Yet, the impact that cell-internalised NPs have on exosome secretion remains largely unknown. Exosomes are ubiquitous cell-released vesicles seemingly involved in numerous biological processes, including regulation of cell-cell communication and disease progression. This enigmatic functional complexity is under the spotlight of a large scientific community in the fields of chemistry, biology and nanomedicine. Only recently, it has been reported that in vitro cellular uptake of platinum and iron oxide NP clusters (~ 100 nm in size) significantly increases the release of exosomes and alters their composition. However, it is unclear whether this evidence reflects a general behaviour or depends on the design of the NPs. A strong need thus arises to explore the mechanistic details of this interaction. Inspired by this challenge, NanoEXOS aims to develop a novel framework to obtain a better and more general understanding of how engineered NPs interfere with the regulatory processes of exosome formation and release. NP-cell studies will be undertaken in vitro to focus on the effects that NPs have on cell-specific exosome samples. Importantly, NanoEXOS will systematically investigate how this interaction depends on the properties of NPs (e.g. well-defined size, shape, surface modification), their biomolecular interactions and their cellular entry mechanism. Overall, NanoEXOS will contribute to expanding our knowledge of how exogenous NPs are processed by living systems. A thorough comprehension of how NPs access and alter key cellular machineries, such as exosome secretion, plays a pivotal role in the biological evaluation of these nanomaterials. This research question is crucial to establish safe and robust biological control over advanced NP-assisted diagnostic and therapeutic strategies.

Keywords: nanoparticles,cell cultures,nanoparticle cell studies,intracellular nanoparticle trafficking,cell imaging,endosomal pathway,exosome biogenesis,exosome analysis,nanosafety,nanomedicine
Novel N-heterocyclic carbene Gold-Selenium complexes: Green Synthesis and Anticancer Activity (DoNoHarm)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Belgium
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2025-07-01
End date: 2027-06-30
Duration (months): 24.0
Total project cost (EUR): 200400.0
EU funding (EUR): 200400.0
Participants: 1
Project status: SIGNED

This project aims to design new anticancer drugs by using N-heterocyclic carbenes (NHC), gold (Au), and selenium (Se), which have not been explored before. NHCs are chosen as key ligands in homogeneous catalysis with transition metals. Gold compounds, like auranofin, disrupt tumor growth by inhibiting key enzymes. Se triggers cancer cell death by inducing oxidative stress and blocking sulfur-based cell components. Cancer poses a global threat, causing millions of deaths and huge economic losses, while available chemotherapy often leads to severe side effects and drug resistance. Therefore, there is a need for more effective and less toxic drugs. I synthesized and tested several drug candidates in in vitro cancer models, showing selective anticancer activity superior to cisplatin. The project uses a "weak base route" to synthesize these new compounds, following green chemistry principles to reduce the ecological impact of chemical synthesis. The proposed synthetic strategy uses non-toxic solvents and energy-saving protocols to promote sustainable drug development. Cell-free and cell-based assays will assess cytotoxicity, efficacy, and selectivity towards the TrxR1 enzyme, which is critical to cancer growth. Molecular docking will confirm the inhibition of the biological target, allowing structure-activity relationship (SAR) analysis to optimize drug structure. By refining the NHC ligand, Au-Se linker, and low core scaffold, the project aims to develop highly effective, targeted anticancer drugs. This research seeks to advance cancer treatment by creating targeted drugs that reduce side effects and improve patient outcomes. Additionally, it aligns with the EU's sustainability goals, promoting environmentally responsible drug development. The project also strengthens European cooperation in cancer research, both in academia and industry, and will inspire future chemists, with broader economic benefits through innovation in healthcare.

Keywords: n heterocyclic carbene nhc complexes,organic synthesis,green chemistry,cancer therapy,anticancer agents,molecular docking
Improving bioproduction through dynamic regulation circuits (BioCircus)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Spain
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2022-06-01
End date: 2024-11-30
Duration (months): 30.0
Total project cost (EUR): 206641.2
EU funding (EUR): 206641.2
Participants: 2
Project status: CLOSED

Biological production of chemicals and materials is a renewable and economically viable alternative to the current chemical processes, easing the transition towards a biology-based circular economy. The current biomanufacturing industry faces a scalability problem. Frequently, producer strains created in the laboratory do not respond well to industrial conditions (e.g., large fermentation volumes, accumulation of toxic intermediates, media acidification, etc.). The goal of BioCircus is to address the issue caused by the lack of robustness of the engineered microbial strains. BioCircus is based on three main research pillars: (1) the construction of biosensor and dynamic regulation circuits that measure and control the production of the target molecule, (2) the use of machine learning predictive models and automation to improve these circuits and (3) validating the designed strains in pre-industrial conditions, closer than standard molecular biology laboratory procedures to real-world bioproduction operations. Naringenin, a key molecule of the flavonoid family, will be used in as proof-of-principle molecule. E. coli will be used as model organism. The design and construction of biosensors and dynamic regulation circuits controlling naringenin production is expected to support the development of methodologies and tools suitable for any other detectable metabolite. BioCircus will produce academic and industrial impacts that will boost the bioproduction field by enabling a shorter strain time-to-market for a wide variety of adaptive and scalable microbial bioproducer strains.

Keywords: biosensors,dynamic regulation,engineering biology,scalable bioproduction,automation,machine learning